Novel Precision Medicines (unspecified)
Head and Neck Cancer, Lung Cancer, Acute Leukemias
Not SpecifiedResearch & Development
Key Facts
Indication
Head and Neck Cancer, Lung Cancer, Acute Leukemias
Phase
Not Specified
Status
Research & Development
Company
About Kura Oncology
Kura Oncology's mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Founded in 2014, the company leverages deep scientific understanding of cancer biology to develop targeted therapies for areas of high unmet need, including head and neck cancer, lung cancer, and acute leukemias. Kura's strategy involves investigating its therapies in combination with standards of care to forge new paths for durable remissions. The company is led by an experienced team and is publicly traded on NASDAQ under the ticker KURA.
View full company profile